16 June 2016

First patient dosed in Phase II clinical trial

Today, the Pediatric Praziquantel Consortium announced that the first patient in a Phase II pediatric clinical trial being conducted in the Ivory Coast has been dosed.

The trial in S. mansoni (schistosomiasis)-infected preschool-age children age 6 years or below will assess the efficacy and safety of two orodispersible tablets formulation candidates (L-PZQ and Rac-PZQ). In preparation for this trial, the consortium team has invested efforts in capacity building, by working closely with the local clinical team to improve the study site facility located in the Man area (Ivory Coast) and by providing the necessary GCP training to the local staff.